Publications by authors named "C Elizabeth Caldon"
Article Synopsis
- - DNA methylation is an important epigenetic mechanism that regulates gene expression, and DNMT inhibitors are used extensively in research to study this process.
- - Researchers developed a CRISPR-based method called SAM-DNMT3A that unexpectedly induces global DNA methylation, regardless of the specific DNA target.
- - This approach reveals a potential therapeutic vulnerability in ER-positive breast cancer and emphasizes the need for careful use of CRISPR technology in methylation studies.
Three-dimensional (3D) epigenome remodeling is an important mechanism of gene deregulation in cancer. However, its potential as a target to counteract therapy resistance remains largely unaddressed. Here, we show that epigenetic therapy with decitabine (5-Aza-mC) suppresses tumor growth in xenograft models of pre-clinical metastatic estrogen receptor positive (ER+) breast tumor.
View Article and Find Full Text PDFPurpose: The addition of PARP inhibitors to chemotherapy has been assessed in > 80 clinical trials across multiple malignancies, on the premise that PARP inhibitors will increase chemotherapy effectiveness regardless of whether cancers have underlying disruption of DNA repair pathways. Consequently, the majority of combination therapy trials have been performed on patients without biomarker selection, despite the use of homologous recombination deficiency to dictate use of PARP inhibitors in the maintenance setting. An unresolved question is whether biomarkers are needed to identify patients who respond to combination PARP inhibitors and chemotherapy.
View Article and Find Full Text PDF